Intellia Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDIntellia Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings growth of 26% provides fundamental context to the price action. However, price is extended 23% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $15.31 | +13.85% | ABOVE |
| 50 SMA | $14.15 | +23.20% | ABOVE |
| 100 SMA | $13.83 | +26.06% | ABOVE |
| 150 SMA | $12.84 | +35.75% | ABOVE |
| 200 SMA | $13.73 | +26.91% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NTLA in an uptrend right now?
NTLA has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is NTLA overbought or oversold?
NTLA's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is NTLA outperforming the market?
NTLA has a Relative Strength (RS) Rating of 82 out of 99. Yes, NTLA is a market leader, outperforming 82% of all stocks over the past 12 months.
Where is NTLA in its 52-week range?
NTLA is trading at $17.43, which is 62% of its 52-week high ($28.25) and 47% above its 52-week low ($7.95).
How volatile is NTLA?
NTLA has a Beta of 2.39 and 52-week volatility of 99%. It's more volatile than the S&P 500 - expect bigger swings.